Tavexia approves a ₹67.19 Cr all-cash Meyonex subscription — 1.5× its own market cap, funding not yet fixed

At a board meeting that ran from 9:30 PM to 10:25 PM on October 7, Tavexia Lifecare — renamed from Sattva Sukun Lifecare only in August, with filings still carrying the mayukh.co.in website and email on the letterhead — approved an acquisition larger than the company itself. The board cleared a subscription to fresh equity of Meyonex Pharmaceuticals Limited, an unlisted pharma company, for ₹67,19,09,760 — i.e. ₹67.19 crore — entirely in cash. At the October 8 close of ₹1.19, Tavexia's 38.36 crore shares are worth about ₹45.6 crore in total. The commitment is roughly 1.5 times the company's own market value, and how it will be paid for has not yet been decided.

The structure matters: this is a subscription to fresh shares, not a purchase from Meyonex's existing shareholders — the ₹67.19 crore would go into Meyonex, whose existing holders keep 1,39,98,120 shares (40%) while Tavexia takes 2,09,97,180 of a post-allotment total of 3,49,95,300 shares. At ₹32 a share, simple arithmetic puts the implied post-money value of Meyonex at about ₹112 crore — more than twice what the market currently pays for all of Tavexia. The disclosure states the acquisition is not related to Tavexia's promoter or promoter group, and allows completion in one or more tranches, with no indicative completion date beyond customary conditions.

The board approved in principle that funds may be raised through equity shares, warrants, debentures or other securities, on a preferential basis or by rights issue. Set that against the company's own accounts: consolidated revenue in Q1 FY27 was ₹0.64 crore with a net loss of ₹0.16 crore, and the December 2025 quarter (Q3 FY26) was also a loss. A ₹67.19 crore raise against a ₹45.6 crore market cap — if done in equity — would imply issuing securities worth well over the company's current value, which suggests either very substantial dilution or the entry of large new investors. That is inference; what the filing states is only that the terms will be decided later.

The disclosure's own numbers do not reconcile cleanly. The turnover rows print "Rs. 13,32075000" for FY2024 and "Rs. 10,79215000" for FY2025 — digit grouping that does not follow standard Indian notation — while a separate row states turnover for the last three financial years as ₹13,99,81,200, i.e. ₹13.99 crore. Read one way the annual figures are an order of magnitude larger than the three-year total. The stated ₹20 crore paid-up capital also does not match the disclosed 1,39,98,120 existing shares of ₹10 face value, which multiply to ₹14.0 crore. These may be typographical errors, but for a ₹67.19 crore cash commitment, the inconsistencies in the target's basic financial description are worth noting — the filing offers no revenue, profit or balance-sheet detail beyond these lines.

1. 20 Aug

   MCA approves the change of name from Sattva Sukun Lifecare to Tavexia Lifecare, in continuation of an intimation dated June 30.

2. 26 Aug

   Pre-open announcement (8:35 AM): entry into pharmaceuticals as a new growth vertical — APIs, intermediates, specialty chemicals, nutraceuticals. The stock closes +19.3% at ₹1.05 on 66 lakh shares.

3. 3 Sept

   Roshan Dealmark Pvt Ltd (promoter group) begins disclosed on-market selling: 14,00,000 shares, holding 6.36% → 6.00%.

4. 4 Sept

   Board meeting scheduled for this day "could not be commenced due to unavoidable circumstances"; adjourned to September 7.

5. 7 Sept

   Adjourned meeting: statutory auditor SSRV & Associates resigns effective the same day citing professional and administrative reasons; a new statutory auditor and a director are appointed; and the board discusses the proposal to acquire up to 60% of Meyonex, authorising preliminary due diligence and negotiations. All filed after close.

6. 28 Sept

   Twelfth disclosed Roshan Dealmark sale tranche; holding down to 3.65%.

7. 1 Oct

   Trading window closes for the September-quarter results.

8. 7 Oct

   Board approves the valuation and due-diligence reports and the acquisition itself: ₹32 a share, ₹67.19 crore, all cash; fund-raising approved in principle only.

9. 8 Oct

   First session after the filing: the stock closes at ₹1.19, −0.8%.

The selling deserves precision. Between September 3 and September 28, Roshan Dealmark Private Limited — a promoter-group entity — disclosed twelve on-market sale tranches totalling 1,05,38,983 shares for approximately ₹1.17 crore (summing the disclosed tranche values), taking its holding from 6.36% to 3.65%. The entire promoter group held 6.39% as of June 30, so Roshan Dealmark accounts for nearly all of it — after these sales the promoter group's stake works out to roughly 3.7%. The filings record the sales and nothing more; no reason is stated. What the record does show is sequence: the selling began September 3 — four days before the Meyonex proposal was first discussed by the board on September 7 — and continued alongside the proposal's progress toward its October 7 approval, with the last disclosed tranche on September 28, before the trading window closed on October 1.

The tape tells its own story. From ₹0.74 on August 24 the stock is up 60.8% in six weeks to ₹1.19, within 4% of its 52-week adjusted high of ₹1.24 set on September 21. Note the sequence at the start of the move: the stock rose 18.9% on August 25 — the session before the pharma-vertical announcement reached the exchange pre-open on August 26 — and another 19.3% on the announcement day itself, on volumes of 42–66 lakh shares against the few-lakh sessions typical through July and early August. The acquisition approval itself added nothing: the first session after the October 7 filing closed down 0.8%. At these prices the entire run has played out between ₹0.49 (the December 2025 low) and ₹1.24, a stock priced in paise either way.